PRQR stock news · ProQR Therapeutics
Get alerts for PRQR
Follow ProQR Therapeutics (PRQR) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PRQRFree on the App Store and Google Play, or on the web.
BofA Securities analyst Alec Stranahan lowered the price target for ProQR Therapeutics from $8 to $7.
NeutralBofA kept its Buy rating on ProQR but cut its price target from $8 to $7. Those mixed comments do not report a change in ProQR's business.